Prescient Therapeutics (ASX: PTX) is a clinical stage oncology company developing personalised medicine approaches to fight cancers that have poorly met or unmet needs. Our technologies include targeted and cellular therapies.

 

PTX-100

PTX-100 is a first in class compound with the ability to block an important cancer growth enzyme known as GGT-1. It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX- 100 is believed to be the only GGT-1 inhibitor in the world in clinical development.

PTX-100 demonstrated safety and encouraging early clinical activity in a Phase 1b study in T cell lymphomas, which is an orphan disease characterised by unmet patient need.
Early clinical data shows that PTX-100 has exceeded efficacy and safety that one might expect from existing therapies for this disease. The US FDA has granted PTX-100 Orphan Drug Designation for all T cell lymphomas. A Phase 2 trial is now planned in T cell lymphomas, which could be a potential registration study.

 

Cell Therapies

CellPryme-M: Prescient's novel, ready-for-the-clinic, CellPryme-M technology enhances adoptive cell therapy performance by shifting T and NK cells towards a more "youthful" cell, improving persistence, and increasing the ability to find and penetrate tumours. CellPryme-M is a 24-hour, non-disruptive process during cell manufacturing. Cell therapies that could benefit from additional productivity in manufacturing or increased potency and durability in-vivo, would be good candidates for CellPryme-M.

CellPryme-A: CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumour microenvironment. CellPryme-A significantly decreases suppressive regulatory T cells; increases expansion of CAR-T cells in vivo; increases tumour penetration of CAR-T cells. CellPryme-A improves tumour killing and host survival of CAR-T cell therapies, and these benefits are even greater when used in conjunction with CellPryme-M pre-treated CAR-T cells.

OmniCAR: is a universal immune receptor platform enabling controllable T-cell activity and multi- antigen targeting with a single cell product. OmniCAR’s modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post- translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets. OmniCAR is in pre-clinical development.

The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens. OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.